Chris Gibson is a really big thinker. The kind of thinker who strives to become an M.D. and a Ph.D at the same time.
That was his plan a few years ago when he was in the University of Utah’s dual degree program studying to become a cardiothoracic surgeon and a researcher. It was in the process of pursuing those degrees when he found himself in a laboratory working with Dr. Dean Li, one of the pre-eminent researchers at the school.
“I had a background in bioengineering, and was working on bringing the engineering mentality to his more traditional biology and genetics lab,” Gibson said. It was during that time when they were working on one disease when he made a discovery.
“I noticed that when you modeled that disease in human cells, the disease cells looked really different,” he explained. The difference was how the cells morphed into something that was totally unlike their original composition.
That relatively minor recognition eventually became the impetus for launching a new kind of biotechnology company that combines information technology and biological research.